Repository logo
 

Dissociable effects of acute SSRI (escitalopram) on executive, learning and emotional functions in healthy humans.

Simple item page
cam.issuedOnline2018-09-26
dc.contributor.authorSkandali, Nikolina
dc.contributor.authorRowe, James B
dc.contributor.authorVoon, Valerie
dc.contributor.authorDeakin, Julia B
dc.contributor.authorCardinal, Rudolf N
dc.contributor.authorCormack, Francesca
dc.contributor.authorPassamonti, Luca
dc.contributor.authorBevan-Jones, William R
dc.contributor.authorRegenthal, Ralf
dc.contributor.authorChamberlain, Samuel R
dc.contributor.authorRobbins, Trevor W
dc.contributor.authorSahakian, Barbara J
dc.contributor.orcidCardinal, Rudolf N [0000-0002-8751-5167]
dc.contributor.orcidRegenthal, Ralf [0000-0002-7292-1859]
dc.contributor.orcidChamberlain, Samuel R [0000-0001-7014-8121]
dc.date.accessioned2018-11-20T00:30:43Z
dc.date.available2018-11-20T00:30:43Z
dc.date.issued2018-12
dc.description.abstractSerotonin is implicated in multiple executive functions including goal-directed learning, cognitive flexibility, response inhibition and emotional regulation. These functions are impaired in several psychiatric disorders, such as depression and obsessive-compulsive disorder. We tested the cognitive effects of the selective serotonin reuptake inhibitor escitalopram, using an acute and clinically relevant dose (20 mg), in 66 healthy male and female volunteers in a double-blind, placebo-controlled study. Participants performed a cognitive test battery including a probabilistic and reversal learning task, the CANTAB intra-dimensional/extra-dimensional shift test of cognitive flexibility, a response inhibition task with interleaved stop-signal and No-Go trials and tasks measuring emotional processing. We showed that acute escitalopram administration impaired learning and cognitive flexibility, but improved the ability to inhibit responses in stop-signal trials while leaving unaffected acute emotional processing. Our findings suggest a dissociation of effects of acute escitalopram on cognitive functions, possibly mediated by differential modulation of brain serotonin levels in distinct functional neural circuits.
dc.description.sponsorshipThis work was supported by a Wellcome Trust Senior Investigator Award to TW Robbins (104631/Z/14/Z) and by the NIHR Cambridge Biomedical Research Centre (Mental Health theme). NS was supported by a Medical Research Council Doctoral Grant Studentship (1432057), JBR by the Wellcome Trust (103838), VV by a Medical Research Council Senior Fellowship (MR/P008747/1), SCR by a Wellcome Trust Clinical Fellowship (110049/Z/15/Z), LP by the Medical Research Council (MR/P01271X/1) and FC employed by Cambridge Cognition. JBR received research grants unrelated to this work from Medical Research Council, James S McDonnell Foundation, PSPAssociation, AZ-Medimmune, Janssen and Lilly, and served as editor for Brain. RR received a grant (16KNO16238) by the Federal Ministry for Economic Affairs and Energy. BJS Consults for Cambridge Cognition, PEAK and Mundipharma, SRC for Cambridge Cognition and Shire, and TWR for Cambridge Cognition, Mundipharma and Unilever, has held research grants from Shionogi and Lundbeck and receives Royalties for CANTAB.
dc.format.mediumPrint-Electronic
dc.identifier.doi10.17863/CAM.27664
dc.identifier.eissn1740-634X
dc.identifier.issn0893-133X
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/285448
dc.languageeng
dc.language.isoeng
dc.publisherSpringer Science and Business Media LLC
dc.publisher.urlhttp://dx.doi.org/10.1038/s41386-018-0229-z
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectAdult
dc.subjectCitalopram
dc.subjectCognition
dc.subjectDissociative Disorders
dc.subjectDouble-Blind Method
dc.subjectEmotions
dc.subjectExecutive Function
dc.subjectFemale
dc.subjectHumans
dc.subjectMale
dc.subjectReversal Learning
dc.subjectSelective Serotonin Reuptake Inhibitors
dc.subjectYoung Adult
dc.titleDissociable effects of acute SSRI (escitalopram) on executive, learning and emotional functions in healthy humans.
dc.typeArticle
dcterms.dateAccepted2018-09-16
prism.endingPage2651
prism.issueIdentifier13
prism.publicationDate2018
prism.publicationNameNeuropsychopharmacology
prism.startingPage2645
prism.volume43
pubs.funder-project-idMRC (1432057)
pubs.funder-project-idWellcome Trust (104631/Z/14/Z)
pubs.funder-project-idMedical Research Council (MR/M009041/1)
pubs.funder-project-idWellcome Trust (110049/Z/15/Z)
pubs.funder-project-idMedical Research Council (MC_U105597119)
pubs.funder-project-idMedical Research Council (MR/M024873/1)
pubs.funder-project-idMedical Research Council (MC_PC_17213)
pubs.funder-project-idMedical Research Council (MC_UU_00005/12)
pubs.funder-project-idMedical Research Council (MR/P008747/1)
pubs.funder-project-idWellcome Trust (103838/Z/14/Z)
pubs.funder-project-idMedical Research Council (MR/P01271X/1)
rioxxterms.licenseref.startdate2018-12
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.typeJournal Article/Review
rioxxterms.versionNA
rioxxterms.versionofrecord10.1038/s41386-018-0229-z

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
s41386-018-0229-z.pdf
Size:
576.79 KB
Format:
Adobe Portable Document Format
Description:
Published version
Licence
https://creativecommons.org/licenses/by/4.0/
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
DepositLicenceAgreementv2.1.pdf
Size:
150.9 KB
Format:
Adobe Portable Document Format
Download

Collections

Cambridge University Research Outputs